Because attrition costs
Advancing the wrong asset is one of the most expensive mistakes in drug development. Teams can spend up to 18 months ranking compounds using in-vivo rodent and simplified in-vitro cell culture models, only for their candidates to fail in late-stage testing.
Through early screening of broader compound libraries directly in viable, intact human tissue, you can confidently prioritize well tolerated compounds with real human efficacy, helping bridge the gap between experimental data and clinical reality.
Apply a translational filter early
Screen broader compound libraries in viable, intact human tissue before your shortlist is fixed, ensuring only compounds with proven, on-target human biology are carried forward.
Rank leads in clinical reality
Evaluate compounds within intact human tissue from multiple donors to capturing patient hetrogeneity and to identify responder / non-responder phenotypes.
Remove weak leads before they scale
Deprioritise targets and compounds that fail to show meaningful activity in human biology before incurring additional unnecessary costs and delays.
Move validated leads into pharmacology with confidence
Our pharmacology studies reveal how therapeutics influence disease biology by measuring pathway modulation, biomarker responses and tissue-level biological effects in viable, intact human tissue. This evidence is generated before IND-enabling work begins, helping strengthen pharmacological understanding early in development.
Our platform
See how our patented bioreactor technology enables viable, intact human tissue to be maintained across extended study durations, so compound behavior can be assessed in the biology that matters.
Related resources
Explore our insights to learn more about how data generated in viable, intact human tissue supports lead prioritization and reduces uncertainty in early development.
Poster
Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices
See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.
The evidence your program demands
Speak to our team about your program.